Indian Investor Interest in Elevation Oncology Surges Amid Stock Volatility Search activity for Elevation Oncology (NASDAQ: ELEV) has risen 56% among Indian investors over the past month, as the stock trades at $0.37, near its 52-week low. Despite a 91% annual decline, analysts maintain a 'buy' rating, citing a potential upside to $1.06 and renewed speculative interest.123